Sanofi Q3 2026 Earnings Recap

Sanofi shares rose 5.9% after earnings, as Q3 sales grew 14.3% to €14.4 billion and management outlined expanded access to immunology compounds through its Regeneron alliance. The longer-term picture still hinges on replenishing the pipeline and managing Dupixent’s loss of exclusivity.

Key Takeaways

• Q3 sales were €14.4 billion, up 14.3% year over year.
• Sanofi discontinued amlitelimab and itepekimab as part of pipeline optimization.
• The expanded Regeneron alliance gives Sanofi access to four new immunology compounds; the company aims to launch its long-acting anti-IL-13 medicine ahead of Dupixent biosimilars.
• Management says Dupixent’s loss of exclusivity is a top priority and expects only a moderate impact on total group revenue, while focusing on preserving earnings and cash flow.
• Sanofi plans to use business development and M&A, particularly late-stage or commercial opportunities, to support growth in immunology, rare diseases, and vaccines.